Suppr超能文献

埃及女性在 COVID-19 后乳腺癌分期趋势的变化:一项回顾性单中心研究。

Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study.

机构信息

68792Ain Shams University, Cairo, Egypt.

Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt.

出版信息

Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231152835. doi: 10.1177/03946320231152835.

Abstract

OBJECTIVES

Since being declared a global pandemic, the SARS-CoV-2 virus had a significant impact on the entire globe. The pandemic has placed a heavy burden on healthcare systems worldwide, and cancer patients are particularly prone. Despite the fact that initial international reports suggest delays in breast cancer (BC) diagnosis and screening programs, the Egyptian context requires additional research on this topic. To examine whether COVID-19 has changed the pattern of disease presentation before and after the pandemic, focusing on the tumor, node, and metastasis (TNM) staging of the disease at the initial presentation.

METHODS

This single-center, retrospective study of female BC patients initially diagnosed at Baheya Foundation was conducted during the following time frames: from Jan 2019 to Jan 2020 (Pre COVID-19 cohort) and from Mar 2020 to Mar 2021 (post-COVID-19 cohort). We compared the two cohorts in terms of clinical characteristics, tumor characteristics, and the number of days from presentation to treatment. Our primary endpoint was the difference in the TNM stage of BC at the initial presentation.

RESULTS

This analysis included 710 BC patients, 350 from the pre-COVID cohort and 360 from the post-COVID group. We detected a 27.9% increase in late-stage BC (stages III-IV) in the post-pandemic cohort compared to the pre-pandemic (60.1% vs. 47%, < 0.001). The time from diagnosis to commencement of treatment was significantly longer (28.34 ± 18.845 vs 36.04 ± 23.641 days, < 0.001) in the post-COVID cohort (mean difference = 7.702, 95% CI 4.54-10.85, < 0.001). A higher percentage of patients in the post-pandemic cohort received systemic neoadjuvant therapy (-value for Exact's test for all treatment options = 0.001).

CONCLUSIONS

The number of patients requiring systemic neoadjuvant chemotherapy increased dramatically in the post-pandemic group with advanced stages of BC at presentation. This study highlights the need for proper management of cancer patients during any future pandemic.

摘要

目的

自宣布全球大流行以来,SARS-CoV-2 病毒对全球产生了重大影响。大流行给全球医疗系统带来了沉重负担,癌症患者尤其容易受到影响。尽管最初的国际报告表明乳腺癌(BC)诊断和筛查计划出现延误,但埃及需要对此类主题进行进一步研究。本研究旨在检查 COVID-19 是否改变了大流行前后疾病表现的模式,重点关注初始表现时疾病的肿瘤、淋巴结和转移(TNM)分期。

方法

本研究为单中心回顾性研究,纳入在 Baheya 基金会首次诊断为乳腺癌的女性患者,时间范围为:2019 年 1 月至 2020 年 1 月(COVID-19 前队列)和 2020 年 3 月至 2021 年 3 月(COVID-19 后队列)。我们比较了两组患者的临床特征、肿瘤特征以及从就诊到治疗的天数。我们的主要终点是初始表现时 BC 的 TNM 分期差异。

结果

本分析纳入了 710 例 BC 患者,COVID-19 前队列 350 例,COVID-19 后队列 360 例。与 COVID-19 前相比,COVID-19 后队列中晚期 BC(III-IV 期)的比例增加了 27.9%(60.1% vs. 47%,<0.001)。COVID-19 后队列从诊断到开始治疗的时间明显延长(28.34 ± 18.845 与 36.04 ± 23.641 天,<0.001)(平均差异=7.702,95%CI 4.54-10.85,<0.001)。COVID-19 后队列中接受全身新辅助治疗的患者比例更高(所有治疗方案的 Exact 检验值为 0.001)。

结论

COVID-19 后队列中,初始表现为晚期 BC 的患者需要接受全身新辅助化疗的比例显著增加。本研究强调了在未来任何大流行期间对癌症患者进行适当管理的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/734e/9869187/2e1c5acbb2d9/10.1177_03946320231152835-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验